Cadence Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

Cadence Capital Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	$2.74M	Sell	45,480 -10,347	-19%	-$623K	0.66%	35
2020 Q2	$3.28M	Buy	55,827 +1,558	+3%	+$93.2K	0.48%	27
2020 Q1	$3.02M	Buy	54,269 +5,385	+11%	+$329K	0.51%	43
2019 Q4	$3.14M	Buy	48,884 +9,660	+25%	+$553K	0.34%	66
2019 Q3	$1.99M	Sell	39,224 -274	-0.7%	-$12.9K	0.28%	139
2019 Q2	$1.79M	Sell	39,498 -12,661	-24%	-$590K	0.18%	177
2019 Q1	$2.49M	Sell	52,159 -1,135	-2%	-$56.5K	0.22%	132
2018 Q4	$2.77M	Sell	53,294 -149,454	-74%	-$8.03M	0.28%	89
2018 Q3	$12.6M	Buy	202,748 +7,754	+4%	+$460K	0.68%	33
2018 Q2	$10.8M	Sell	194,994 -20,497	-10%	-$1.11M	0.64%	39
2018 Q1	$13.6M	Buy	215,491 +13,061	+6%	+$840K	0.89%	10
2017 Q4	$12.4M	Sell	202,430 -7,805	-4%	-$488K	0.79%	27
2017 Q3	$13.4M	Buy	210,235 +15,803	+8%	+$923K	0.84%	18
2017 Q2	$10.8M	Sell	194,432 -7,182	-4%	-$391K	0.75%	33
2017 Q1	$11M	Buy	201,614 +13,648	+7%	+$749K	0.76%	38
2016 Q4	$11M	Sell	187,966 -2,317	-1%	-$127K	0.77%	36
2016 Q3	$10.3M	Buy	+190,283	New	+$12.2M	0.75%	37
2015 Q4	–	Sell	-208,831	Closed	-$12.4M	–	612
2015 Q3	$12.4M	Sell	208,831 -18,593	-8%	-$1.18M	0.87%	27
2015 Q2	$15.1M	Buy	227,424 +36,133	+19%	+$2.38M	0.84%	16
2015 Q1	$12.3M	Sell	191,291 -27,742	-13%	-$1.74M	0.75%	36
2014 Q4	$12.9M	Sell	219,033 -77,687	-26%	-$4.38M	0.75%	35
2014 Q3	$15.2M	Buy	296,720 +46,563	+19%	+$2.33M	0.8%	17
2014 Q2	$12.1M	Buy	250,157 +15,624	+7%	+$770K	0.58%	24
2014 Q1	$12.2M	Sell	234,533 -10,256	-4%	-$546K	0.51%	30
2013 Q4	$13M	Sell	244,789 -37,019	-13%	-$1.89M	0.49%	36
2013 Q3	$13M	Buy	+281,808	New	+$12.4M	0.44%	23

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

Cadence Capital Management's BMY Position: Q3 2020 in Review

Cadence Capital Management reduced its Bristol-Myers Squibb (BMY) stake by 19% in Q3 2020, selling an estimated $623K and leaving 45,480 shares worth $2.74M. The position accounts for 0.66% of the portfolio, ranked #35.

Cadence Capital Management first reported a position in BMY in Q3 2013 and has held it in 26 quarters since. The position peaked at $15.2M in Q3 2014. 2,214 funds tracked by Wall St. Rank hold BMY as of Q3 2020.

Cadence Capital Management held 45,480 shares of Bristol-Myers Squibb worth $2.74M as of Q3 2020.
Cadence Capital Management sold 10,347 Bristol-Myers Squibb shares in Q3 2020, an estimated $623K.
Bristol-Myers Squibb made up 0.66% of Cadence Capital Management's portfolio in Q3 2020, its #35 holding.
Cadence Capital Management first reported a position in Bristol-Myers Squibb in Q3 2013 and has held it in 26 quarters since.
Cadence Capital Management's Bristol-Myers Squibb position peaked at $15.2M in Q3 2014.
2,214 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2020.

Based on Cadence Capital Management's 13F filing for Q3 2020, filed 16 Oct 2020.